PRICES include / exclude VAT
Homepage>BS Standards>11 HEALTH CARE TECHNOLOGY>11.100 Laboratory medicine>11.100.10 In vitro diagnostic test systems>BS ISO 21474-1:2020 In vitro diagnostic medical devices. Multiplex molecular testing for nucleic acids Terminology and general requirements for nucleic acid quality evaluation
Sponsored link
immediate downloadReleased: 2020-08-24
BS ISO 21474-1:2020 In vitro diagnostic medical devices. Multiplex molecular testing for nucleic acids Terminology and general requirements for nucleic acid quality evaluation

BS ISO 21474-1:2020

In vitro diagnostic medical devices. Multiplex molecular testing for nucleic acids Terminology and general requirements for nucleic acid quality evaluation

Format
Availability
Price and currency
English Secure PDF
Immediate download
270.40 USD
English Hardcopy
In stock
270.40 USD
Standard number:BS ISO 21474-1:2020
Pages:32
Released:2020-08-24
ISBN:978 0 580 98656 7
Status:Standard
DESCRIPTION

BS ISO 21474-1:2020


This standard BS ISO 21474-1:2020 In vitro diagnostic medical devices. Multiplex molecular testing for nucleic acids is classified in these ICS categories:
  • 11.100.10 In vitro diagnostic test systems

This document provides the terms and general requirements for the evaluation of the quality of nucleic acids as the analytes for multiplex molecular tests, which simultaneously identify two or more nucleic acid target sequences of interest. This document is applicable to all multiplex molecular methods used for examination using in vitro diagnostic (IVD) medical devices and laboratory developed tests (LDTs). It provides information for both qualitative and quantitative detection of nucleic acid target sequences.

This document is intended as guidance for multiplex molecular assays that detect and/or quantify human nucleic acid target sequences or microbial pathogen nucleic acid target sequences from human clinical specimens. This document is applicable to any molecular in vitro diagnostic examination performed by medical laboratories. It is also intended to be used by laboratory customers, in vitro diagnostics developers and manufacturers, biobanks, institutions and commercial organizations performing biomedical research, and regulatory authorities. This document is not applicable to metagenomics.

NOTE

An examination procedure developed for a laboratory’s own use is often referred to as a “laboratory developed test”, “LDT”, or “ in-house test”.